Search | Médecins Sans Frontières Access Campaign

2867 results found
There are 0 active filters

2867 results found

A member of MSF’s mobile vaccination team prepares a dose of COVID vaccine at a nursing home in Shayle, Lebanon, 2021

Statement |

20 September 2023

MSF statement on UN pandemic preparedness meeting and declaration

Future global health emergency responses must be equitable and address people’s needs

For over 20 years, MSF has provided HIV care in Homa Bay, Kenya, the area with the highest rate of HIV infection in the country. 2020.

Statement |

20 September 2023

MSF reaction statement to UNHLM PPPR declaration

MSF reacts to 2023 UN High-Level Meeting on Pandemic Prevention, Preparedness and Response (PPPR) declaration

GeneXpert test cartridge being used to test a sample of suspected TB in MSF’s lab at Bangassou Hospital, Central African Republic, 2017.

Press release |

19 September 2023

TB test price reduction by Cepheid and Danaher is an important step in the right direction

Cepheid and Danaher have just announced that they are reducing the price of the Xpert MTB/RIF test by 20% in high-TB-burden countries, from US$9.98 to $7.97 per test. This reduction is a significant step, considering the corporations ...

Tags Tuberculosis drug-resistant TBtuberculosis GeneXpert Johnson & Johnson

Bottle of bedaquiline, Zhytomyr Regional TB Dispensary, Ukraine. In 2018, MSF started providing treatment for drug-resistant TB to people in Zhytomyr, Ukraine.

Photo credit: Oksana Parafeniuk

Blog |

16 September 2023

The long and winding road to ensure affordable access to a key TB drug

With the United Nations High-Level meeting just over the horizon, the TB community is ready to amplify the voices of people affected by TB around the world at this global forum, and demand the global attention and resources needed to beat this devastating yet curable disease.

Technical brief |

15 September 2023

From TRIPS to PPR: Addressing Intellectual Property Barriers on Lifesaving Medical Products

The ongoing PPR negotiations at WHO offer an opportunity to resolve the decades-long tension between IP and access

Tags Intellectual property and trade coronavirus TRIPS WTO

Technical brief |

12 September 2023

“Time for $5” Campaign: Questions and Answers

Q&A on “Time for $5”, a campaign for affordable diagnostic tests

Tags Diagnostics tuberculosis GeneXpert Cepheid Time for $5

Fact sheet |

12 September 2023

Factsheet: “Time for $5” Campaign

The “Time for $5” campaign calls on Cepheid and its parent corporation, Danaher, to prioritise people over profits and reduce the price of GeneXpert tests to $5

Tags Diagnostics tuberculosis GeneXpert Cepheid Time for $5

Video |

12 September 2023

Time for $5 Campaign video

The 'Time for $5' Campaign calls on Cepheid and its parent corporation Danaher to drop the price of GeneXpert tests to $5 a test.

Tags Diagnostics GeneXpert Cepheid Time for $5

Cepheid's price gouging for lifesaving test

Time for $5 graphics

Press release |

12 September 2023

Ahead of UN TB High-Level Meeting, US corporations J&J and Cepheid must pledge access to lifesaving TB medicines and tests for everyone in need

MSF calls on J&J and Cepheid/Danaher to commit to improving access to key TB drug and test by UNHLM 22 September

Tags DiagnosticsTuberculosis

Newsletter |

12 September 2023

Join the Time for $5 campaign to save millions of lives

Today we hit the road running with our campaign, ‘Time for $5’, calling on the US company Cepheid, and its parent corporation Danaher, to drop the price of a lifesaving test, GeneXpert, to save millions of people’s lives around the world.

Research article |

11 September 2023

The Lancet Child & Adolescent Health: Reversing the neglect of children and adolescents affected by tuberculosis

MSF and co-authors call for commitments from countries at the UNHLM on TB to address gaps in TB care for children and adolescents.

Tags Tuberculosis tuberculosis

07 September 2023

Campaign Newsletter

Tags tuberculosis Time for $5

A clinician gathering antiretroviral medications for a patient at Maram Dispensary in Ndhiwa sub county, Homa Bay County, Kenya, 2021

Press release |

17 August 2023

MSF refuses to sign ViiV’s last-minute NDA for access to most-effective HIV prevention drug CAB-LA

MSF urges ViiV to withdraw problematic purchasing conditions hindering access to HIV prevention drug CAB-LA

Tags HIV/AIDS HIV/AIDS cabotegravir ViiV

Mr and Ms Kimboi, both of whom are living with HIV, picking up their medicines at the MSF Chakpikarong clinic, Thailand, 2019

Letter |

17 August 2023

Open letter to ViiV to improve access to HIV prevention drug CAB-LA

MSF letter to ViiV asking the company to withdraw problematic purchasing conditions for HIV prevention drug CAB-LA

Tags HIV/AIDS HIV/AIDS cabotegravir ViiV

Technical brief |

17 August 2023

Q&A: Access to cabotegravir long-acting (CAB-LA) for HIV pre-exposure prophylaxis (PrEP)

Q&A on access to HIV prevention drug CAB-LA

Tags HIV/AIDS HIV/AIDS cabotegravir ViiV

Video |

17 August 2023

Testimonies for access to HIV prevention drug CAB-LA

CAB-LA is a game-changing HIV prevention medicine, but access to it is currently a challenge.

Tags HIV/AIDS HIV/AIDS cabotegravir

Moussa, type I diabetes patient, in MSF project in Arsal, Lebanon.

Feature story |

07 August 2023

Moussa's story: Access to insulin pens in humanitarian settings

tbc

Tags Diabetes Diabetes Insulin

Letter |

31 July 2023

Open letter: Requesting clarification from J&J on the recent deal for generic bedaquiline supply

Open letter by CSOs to US pharma J&J seeking clarification on the deal for supply of generic versions of TB bedaquiline

Tags Tuberculosis drug-resistant TBtuberculosis bedaquiline Johnson & Johnson

MSF medical staff administers measles vaccinations to children in Ndjala village, Drodro Ituri province, Democratic Republic of Congo, May 2023

Press release |

18 July 2023

Gavi must do more as WHO/UNICEF estimates show slow childhood vaccination recovery

MSF again called on Gavi to broaden catch-up vaccine coverage for children by waiving co-financing requirements of countries with fragile health systems

Tags Vaccines Gavi, the Vaccine Alliance

Date

Primary topics

Types of content

Products

Diseases

General Terms

Geography

Campaigns

Institutions & Events

Report series

Miscellaneous

MSF statement on UN pandemic preparedness meeting and declaration

MSF reaction statement to UNHLM PPPR declaration

TB test price reduction by Cepheid and Danaher is an important step in the right direction

The long and winding road to ensure affordable access to a key TB drug

From TRIPS to PPR: Addressing Intellectual Property Barriers on Lifesaving Medical Products

“Time for $5” Campaign: Questions and Answers

Factsheet: “Time for $5” Campaign

Time for $5 Campaign video

Time for $5 graphics

Ahead of UN TB High-Level Meeting, US corporations J&J and Cepheid must pledge access to lifesaving TB medicines and tests for everyone in need

Join the Time for $5 campaign to save millions of lives

The Lancet Child & Adolescent Health: Reversing the neglect of children and adolescents affected by tuberculosis

Campaign Newsletter

MSF refuses to sign ViiV’s last-minute NDA for access to most-effective HIV prevention drug CAB-LA

Open letter to ViiV to improve access to HIV prevention drug CAB-LA

Q&A: Access to cabotegravir long-acting (CAB-LA) for HIV pre-exposure prophylaxis (PrEP)

Testimonies for access to HIV prevention drug CAB-LA

Moussa's story: Access to insulin pens in humanitarian settings

Open letter: Requesting clarification from J&J on the recent deal for generic bedaquiline supply

Gavi must do more as WHO/UNICEF estimates show slow childhood vaccination recovery